---
title: "SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293038700.md"
description: "On July 17, 2026, SystImmune Inc. revealed that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd., obtained regulatory clearance from China's National Medical Products Administration (NMPA) for izalontamab (iza-bren)."
datetime: "2026-07-17T12:27:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293038700.md)
  - [en](https://longbridge.com/en/news/293038700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293038700.md)
generator: "portal-rs"
---

# SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

On July 17, 2026, SystImmune Inc. revealed that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd., obtained regulatory clearance from China's National Medical Products Administration (NMPA) for izalontamab (iza-bren).

### Related Stocks

- [688506.CN](https://longbridge.com/en/quote/688506.CN.md)
- [02615.HK](https://longbridge.com/en/quote/02615.HK.md)

## Related News & Research

- [Lotus Lake portfolio company Immupeutics wins China IND clearance for IPM514 mRNA vaccine in lung squamous cancer](https://longbridge.com/en/news/296847935.md)
- [NorthCore Life’s LotosPFA wins China NMPA approval for nano pulsed-field ablation system](https://longbridge.com/en/news/297260650.md)
- [Akeso says Phase III ivonescimab-chemo trial in biliary tract cancer meets overall survival endpoint](https://longbridge.com/en/news/297257007.md)
- [CF PharmTech says NMPA clears ICF001 trials in IPF, PPF](https://longbridge.com/en/news/296781313.md)
- [MicroPort Endovastec Aorfix endograft wins China NMPA green-channel designation](https://longbridge.com/en/news/297207213.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**